Both conditions independently contribute to CVD, but together they amplify the risk and severity of cardiovascular complications.

Obesity and ageing exhibit overlapping molecular and cellular pathways (e.g., inflammation, oxidative stress, mitochondrial dysfunction) that accelerate cardiovascular ageing.

Evidence supports that weight loss not only reduces major cardiovascular events in older adults but also promotes healthy ageing even in non-obese individuals.

Excess weight may mimic or intensify age-related changes in the cardiovascular system, leading to earlier onset or more rapid progression of CVD.

Emerging therapies targeting obesity (e.g., GLP-1 receptor agonists, caloric restriction mimetics) may simultaneously counteract mechanisms of ageing, offering dual protection.

Understanding the convergence of obesity and ageing can guide the development of novel, targeted therapies to address CVD in an increasingly aged and obese global population.

Future strategies should consider age, weight status, and molecular profiles to optimize cardiovascular risk management.

Obesity accelerates cardiovascular ageing through shared molecular pathways, and targeting obesity with metabolic interventions may offer a dual benefit reducing cardiovascular risk while counteracting ageing-related decline.